Diferencia entre revisiones de «Ganciclovir»

(Text replacement - "HTN" to "hypertension")
(Restore original dosing content alongside dynamic SMW tables)
 
(No se muestran 9 ediciones intermedias de 5 usuarios)
Línea 1: Línea 1:
==Administration==
==Administration==
*Type: Antiviral
*Type: [[Antiviral]]
*Routes of Administration: IV, PO
*Routes of Administration: IV, PO
*Common Trade Names: Cytovene
*Common Trade Names: Cytovene
Línea 17: Línea 17:
**Maintenance treatment, IV route: 5mg/kg IV 5-7x/wk; Alt: 6mg/kg IV 5x/wk; Info: not 1st-line agent
**Maintenance treatment, IV route: 5mg/kg IV 5-7x/wk; Alt: 6mg/kg IV 5x/wk; Info: not 1st-line agent
**Maintenance treatment, PO route: 1000mg PO tid; Alt: 500mg PO q3h while awake (6 doses/day); Info: not 1st-line agent; give with food
**Maintenance treatment, PO route: 1000mg PO tid; Alt: 500mg PO q3h while awake (6 doses/day); Info: not 1st-line agent; give with food
===Indications by Disease===
{{#ask: [[Has DrugName::Ganciclovir]] [[Has Population::Adult]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Pediatric Dosing==
==Pediatric Dosing==
Línea 34: Línea 47:
*[[CMV]] infection, congenital (<1 mo)
*[[CMV]] infection, congenital (<1 mo)
**6mg/kg IV q12h x6wk
**6mg/kg IV q12h x6wk
===Indications by Disease===
{{#ask: [[Has DrugName::Ganciclovir]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Special Populations==
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*[[Lactation risk categories|Lactation risk]]:
*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out
===Renal Dosing===
===Renal Dosing===
*IV route, induction treatment: CrCl 50-69: 2.5mg/kg q12h; CrCl 25-49: 2.5mg/kg q24h; CrCl 10-24: 1.25mg/kg q24h; CrCl <10: 1.25mg/kg 3x/wk; HD: give dose after dialysis, no supplement
*IV route, induction treatment: CrCl 50-69: 2.5mg/kg q12h; CrCl 25-49: 2.5mg/kg q24h; CrCl 10-24: 1.25mg/kg q24h; CrCl <10: 1.25mg/kg 3x/wk; HD: give dose after dialysis, no supplement
*IV route, maintenance treatment: CrCl 50-69: 2.5mg/kg q24h; CrCl 25-49: 1.25mg/kg q24h; CrCl 10-24: 0.625mg/kg q24h; CrCl <10: 0.625mg/kg 3x/wk; HD: give dose after dialysis, no supplement
*IV route, maintenance treatment: CrCl 50-69: 2.5mg/kg q24h; CrCl 25-49: 1.25mg/kg q24h; CrCl 10-24: 0.625mg/kg q24h; CrCl <10: 0.625mg/kg 3x/wk; HD: give dose after dialysis, no supplement
*PO route: CrCl 50-69: 1500mg/day divided qd-tid; CrCl 25-49: 1000mg/day divided qd-bid; CrCl 10-24: 500mg qd; CrCl <10: 500mg 3x/wk; HD: give dose after dialysis, no supplement
*PO route: CrCl 50-69: 1500mg/day divided QD-tid; CrCl 25-49: 1000mg/day divided QD-bid; CrCl 10-24: 500mg QD; CrCl <10: 500mg 3x/wk; HD: give dose after dialysis, no supplement


==Contraindications==
==Contraindications==
*Allergy to class/drug
*Allergy to class/drug
*hypersens. to acyclovir
* ANC < 500
*ANC <500
* Platelets < 25,000
*Plt <25,000


==Adverse Reactions==
==Adverse Reactions==
Línea 64: Línea 89:
*[[fever]]
*[[fever]]
*[[leukopenia]]
*[[leukopenia]]
*[[anorexia]]
*anorexia
*[[vomiting]]
*[[vomiting]]


Línea 84: Línea 109:


[[Category:Pharmacology]]
[[Category:Pharmacology]]
[[Category:ID]]

Revisión actual - 02:37 20 mar 2026

Administration

  • Type: Antiviral
  • Routes of Administration: IV, PO
  • Common Trade Names: Cytovene

Adult Dosing

  • CMV prophylaxis, solid organ transplant
    • IV route: 5mg/kg IV q12h x7-14 days, then 5mg/kg IV q24h or 6mg/kg IV 5x/wk
    • PO route: 1000mg PO tid, give with food
  • CMV prophylaxis, HIV-assoc.
    • IV route: 5mg/kg IV 5-7x/wk; Info: not 1st-line agent
    • PO route: 1000mg PO tid; Info: not 1st-line agent; give with food
  • CMV retinitis, immunocompromised patients
    • Induction treatment: 5mg/kg IV q12h x14-21 days; Info: not 1st-line agent
    • Maintenance treatment, IV route: 5mg/kg IV 5-7x/wk; Alt: 6mg/kg IV 5x/wk; Info: not 1st-line agent
    • Maintenance treatment, PO route: 1000mg PO tid; Alt: 500mg PO q3h while awake (6 doses/day); Info: not 1st-line agent; give with food


Indications by Disease

DiseaseDoseContext
CMV colitis5mg/kg IV q12hrs x 21 daysUntil symptom resolution
CMV neurologic disease5mg/kg IV q12hrs x 21 days then 5mg/kg IV q24hrsCombined with Foscarnet
CMV pneumonia5mg/kg IV q12hrs x 3 weeksCMV pneumonia
Encephalitis5mg/kg IV every 12hrCMV

Pediatric Dosing

Off label use as pediatric medication

  • CMV prophylaxis, solid organ transplant
    • Induction: 5mg/kg IV q12h x7-14 days
    • Maintenance: 5mg/kg IV q24h; Alt: 6mg/kg IV 5x/wk
  • CMV prophylaxis, HIV-assoc
    • 5mg/kg IV q24h
  • CMV infection
    • Induction: 5mg/kg IV q12h x14-21 days; Info: may increase dose to 7.5mg/kg IV q12h
    • Maintenance: 5mg/kg IV q24h; Alt: 6mg/kg IV 5x/wk
  • CMV infection, congenital (<1 mo)
    • 6mg/kg IV q12h x6wk


Indications by Disease

DiseaseDoseContext
Encephalitis5mg/kg IV q12hrsPediatric CMV

Special Populations

Renal Dosing

  • IV route, induction treatment: CrCl 50-69: 2.5mg/kg q12h; CrCl 25-49: 2.5mg/kg q24h; CrCl 10-24: 1.25mg/kg q24h; CrCl <10: 1.25mg/kg 3x/wk; HD: give dose after dialysis, no supplement
  • IV route, maintenance treatment: CrCl 50-69: 2.5mg/kg q24h; CrCl 25-49: 1.25mg/kg q24h; CrCl 10-24: 0.625mg/kg q24h; CrCl <10: 0.625mg/kg 3x/wk; HD: give dose after dialysis, no supplement
  • PO route: CrCl 50-69: 1500mg/day divided QD-tid; CrCl 25-49: 1000mg/day divided QD-bid; CrCl 10-24: 500mg QD; CrCl <10: 500mg 3x/wk; HD: give dose after dialysis, no supplement

Contraindications

  • Allergy to class/drug
  • ANC < 500
  • Platelets < 25,000

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 3hr
  • Metabolism: CYP450
  • Excretion: Urine

Mechanism of Action

Inhibits DNA polymerase and incorporates into viral DNA

Comments

See Also

References

Epocrates, UpToDate

Obtenido de «https://www.wikem.org/w/index.php?title=Ganciclovir&oldid=386553»